Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07111260

Efficacy of pHA130 Hemoadsorption for 4 Hours (p4H Study)

This is an open-label, randomized, crossover study to evaluate the efficacy of extending the duration of hemoadsorption (HA) combined with hemodialysis (HD) from 2 hours to 4 hours for clearing protein-bound uremic toxins, such as Indoxyl Sulfate (IS), in stable maintenance hemodialysis patients. Patients will be randomized to receive either 2-hour HA or 4-hour HA once a week for 8 weeks, then cross over to the other treatment for another 8 weeks after a 2-week washout period. The primary endpoint is the reduction rate of IS.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

End Stage Renal Disease on Dialysis

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Peking University People's Hospital

Beijing, Beijing Municipality, China

Location status: Recruiting

Location contact

Liangying Gan

CONTACT

[email protected]

010-88324516

About this study

Patients with end-stage renal disease (ESRD) on maintenance hemodialysis (MHD) have a high burden of uremic toxins, particularly protein-bound uremic toxins (PBUTs), which are poorly cleared by conventional dialysis and are associated with high cardiovascular mortality. hemoadsorption (HA) is an adjunctive blood purification technique effective at removing PBUTs. The standard duration for HA sessions is typically 2-2.5 hours. However, emerging evidence suggests that extending the treatment duration may enhance toxin removal. This study aims to rigorously compare the efficacy and safety of a 4-hour HA session combined with hemodialysis against a standard 2-hour session in clearing key PBUTs like Indoxyl Sulfate (IS) and p-Cresyl Sulfate (PCS). The findings will provide crucial evidence for optimizing HA treatment protocols to improve toxin clearance and potentially patient outcomes in the ESRD population.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 75 years, regardless of gender
  • Stable maintenance hemodialysis for ≥3 months, with a relatively fixed dialysis regimen
  • Receiving hemodialysis 3 times per week, each session lasting ≥4 hours
  • Single-pool Kt/V (spKt/V) ≥1.2 within 8 weeks prior to enrollment
  • Willing and able to sign the informed consent form

Exclusion criteria

  • Life expectancy less than 1 year
  • White blood cell count < 4 × 10⁹/L and/or platelet count < 60 × 10⁹/L
  • Active or chronic gastrointestinal bleeding, or diagnosed coagulation disorders
  • Active malignant tumor
  • Active infection
  • Pregnant or breastfeeding
  • Participation in another clinical trial within the past month or currently enrolled in one
  • Deemed unsuitable for the study by the investigator

Treatment and study plan

pHA130 Hemoadsorption + High-Flux Hemodialysis

Device

A combination blood-purification procedure in which a pHA130 hemoperfusion cartridge is connected in series with a high-flux hemodialyzer. Blood first passes through the HP cartridge to adsorb protein-bound uremic toxins and is then dialyzed. In the 4-hour arm the HP cartridge remains online for the entire 4-hour session; in the 2-hour arm the cartridge is removed after 2 hours and dialysis continues alone for the remaining 2 hours. Blood-flow rates are 250-350 mL/min (4-hour arm) or 200-250 mL/min (2-hour arm).

Primary outcomes

  1. Reduction Rate of Serum Indoxyl Sulfate (IS)

    Time frame: At Week 1, Week 8, Week 11, and Week 18; blood samples will be collected at 0 hours (before treatment), 2 hours after treatment begins, and 4 hours (end of treatment) during each visit

    The reduction rate (RR) of serum Indoxyl Sulfate (IS) after a single HAHD treatment session. The RR is calculated as: RR(%) = (1 - (Post-treatment Concentration / Pre-treatment Concentration)) × 100. Post-treatment concentration will be corrected for hemoconcentration.

Secondary outcomes

  1. Reduction Rate of p-Cresyl Sulfate (PCS)

    Time frame: At Week 1, Week 8, Week 11, and Week 18; blood samples will be collected at 0 hours (before treatment), 2 hours after treatment begins, and 4 hours (end of treatment) during each visit

    RR of serum PCS after a single session

  2. Change from Baseline in Pre-dialysis IS levels

    Time frame: Baseline (Week 1) to end of period 1 (Week 8); Baseline of period 2 (Week 11) to end of period 2 (Week 18)

    Change in pre-dialysis serum concentrations of IS from the beginning to the end of each 8-week treatment period

  3. Change from Baseline in Pre-dialysis PCS levels

    Time frame: Baseline (Week 1) to end of period 1 (Week 8); Baseline of period 2 (Week 11) to end of period 2 (Week 18)

    Change in pre-dialysis serum concentrations of PCS from the beginning to the end of each 8-week treatment period

  4. Clearance of Other Uremic Toxins

    Time frame: Week 1, Week 8, Week 11, Week 18

    Reduction rates and/or clearance of urea, creatinine, β2-microglobulin, C-reactive protein (CRP), and Interleukin-6 (IL-6)

  5. Number of Participants With Adverse Events, Circuit Coagulation, and Abnormal Changes in Vital Signs or Laboratory Parameters

    Time frame: Throughout the entire study duration (up to 18 weeks)

    All adverse events (AEs) reported during the study will be recorded and assessed for severity and relationship to the intervention. Specific safety indicators include the incidence of circuit coagulation, decreases in white blood cell count, platelet count, and hemoglobin levels, as well as changes in vital signs.

Study contacts

Contact information is provided by the study sponsor or research team.

Liangying Gan

CONTACT

[email protected]

010-88324516

Sponsors and collaborators

Lead sponsor

Peking University People's Hospital

Other

Registry information

Official study title

Comparison of the Efficacy of Hemoadsorption Combined With Hemodialysis of Different Treatment Durations in Clearing Protein-Bound Uremic Toxins: A Randomized Crossover Controlled Trial

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Aug 8, 2025
Registry last updated
Aug 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.